Sorafenib/Regorafenib and Lapatinib Interact to kill CNS Tumor Cells

Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens

(2013) Filippo Pietrantonio et al.   CANCER BIOLOGY & THERAPY

A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors

(2013) Haibiao Gong et al.   CANCER BIOLOGY & THERAPY

Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy

(2013) Nichola Cruickshanks et al.   CANCER BIOLOGY & THERAPY

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients

(2013) Monic Roengvoraphoj et al.   CANCER TREATMENT REVIEWS

A Proposal Regarding Reporting of In Vitro Testing Results

(2013) M. A. Smith et al.   CLINICAL CANCER RESEARCH

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma

(2013) D. A. Reardon et al.   CLINICAL CANCER RESEARCH

Glioblastoma and Other Malignant Gliomas

(2013) Antonio Omuro   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients

(2013) David Akhavan et al.   Cancer Discovery

OSU-03012 interacts with lapatinib to kill brain cancer cells

(2012) Laurence Booth et al.   CANCER BIOLOGY & THERAPY

Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling

(2012) M. Danielle Bareford et al.   CANCER BIOLOGY & THERAPY

Effects of low concentrations of Regorafenib and Sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro

(2012) Brian I. Carr et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240

(2012) T. R. Fenton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells

(2011) M. D. Bareford et al.   CANCER RESEARCH

Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients

(2011) Maria Cristina Villarroel et al.   INVESTIGATIONAL NEW DRUGS

Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

(2010) Margaret A. Park et al.   CANCER BIOLOGY & THERAPY

EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence

(2010) Anna Elisa Quatrale   Frontiers in Bioscience-Landmark

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

(2010) K W Pratz et al.   LEUKEMIA

Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells

(2010) Margaret A. Park et al.   MOLECULAR CANCER THERAPEUTICS

BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing

(2009) A. P. Martin et al.   MOLECULAR PHARMACOLOGY